I agree with hottod. I think the FDA would take a very dim view if it thought Acadia/Neuren were trying to mount a public campaign to win approval. Also, before the last trial, Neuren specifically requested parents of children involved NOT to publish anything about their experiences on social media. There are many reasons, but one is that positive commentary could affect trial results, especially as one of the key measures is an assessment given by care givers. Many posters here have been critical of Neuren management - sometimes with good reason - but one thing management has done well is establish a good working relationship with the FDA. Why would they jeopardise that?
NEU Price at posting:
$1.26 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)